Neumora Therapeutics, Inc. Common Stock

€1.391
EUR
Last updated on --.
24h volume2.12K
24h highest1.4086 EUR
24h lowest1.4086 EUR
24h Price movement-0.62%

NMRA recent prices

24 Hours
-0.62%-€0.008642
30 days
-13.90%-€0.22469
60 days
-21.08%-€0.37161
90 days
-52.30%-€1.526

Key data

Previous close1.4000 EUR
Market cap261.00M EUR
Volume2.12K
P/E ratio--
Dividend yield (TTM)0.00%
Dividend amount--
Next ex-dividend date--
Next payment date--
EPS diluted (TTM)-1.0370 EUR
Net income (FY)-192.19M EUR
Revenue (FY)--
Last report dateMay 7, 2026

About Neumora Therapeutics, Inc. Common Stock

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
HeadquartersWATERTOWN
Employees (FY)92.00
Net income per employee (FY)-2.09M EUR
Listed onNasdaq
Official website

NMRA conversion tables

NMRANMRA
EUREUR
0.5 NMRA0.69568 EUR
1 NMRA1.391 EUR
5 NMRA6.956 EUR
10 NMRA13.91 EUR
EUREUR
NMRANMRA
0.5 EUR0.35936 NMRA
1 EUR0.71872 NMRA
5 EUR3.593 NMRA
10 EUR7.187 NMRA

FAQ

NMRA is trading at €1.391, -0.62% over the last 24 hours. Track live moves on the price chart at the top of this page.
The NMRA stock forecast depends on a mix of factors — broader market conditions, sector trends, and company-specific drivers like earnings, product cycles, and macro signals. NMRA is currently trading at €1.391, -0.62% over the last 24 hours, which reflects how the market is pricing these factors today. For a longer-term outlook on NMRA price action, review the 30-day, 60-day, and 90-day performance shown above, monitor momentum across the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, and watch overall market sentiment. Stock forecasts and price predictions are inherently uncertain — always DYOR.
P/E ratio (Price-to-Earnings, trailing twelve months) measures how much investors pay per dollar of earnings over the last 12 months. NMRA's P/E ratio is currently -- — calculated by dividing its share price by its trailing 12-month earnings per share (EPS). A higher P/E suggests investors expect stronger future growth from NMRA; a lower P/E may indicate the stock is undervalued or that the market is pricing in a weaker outlook. P/E ratios are most useful when compared against NMRA's historical range and other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.
Neumora Therapeutics, Inc. Common Stock's market cap is currently 261.00M EUR. Market cap is calculated as stock price × total shares outstanding.

Disclaimer

The social content on this page ("Content"), including but not limited to tweets and statistics provided by LunarCrush, is sourced from third parties and provided "as is" for informational purposes only. OKX does not guarantee the quality or accuracy of the Content, and the Content does not represent the views of OKX. It is not intended to provide (i) investment advice or recommendation; (ii) an offer or solicitation to buy, sell or hold digital assets; or (iii) financial, accounting, legal or tax advice. Digital assets, including stablecoins and NFTs, involve a high degree of risk and can fluctuate greatly. The price and performance of the digital assets are not guaranteed and may change without notice.

OKX does not provide investment or asset recommendations. You should carefully consider whether trading or holding digital assets is suitable for you in light of your financial condition. Please consult your legal/tax/investment professional for questions about your specific circumstances. For further details, please refer to our Terms of Use and Risk Warning.
24h volume2.12K
24h highest1.4086 EUR
24h lowest1.4086 EUR
24h Price movement-0.62%
NMRANMRA
EUREUR
Start trade with NMRA Perpetual